BR9913400A - Formulação oral de liberação imediata na forma sólida de um inibidor de trombina, uso de um inibidor de trombina baseado em peptìdeo de baixo peso molecular, processos para a profilaxia e/ou o tratamento de trombo-embolismo, e para a preparação de uma formulação oral de liberação imediata, e, uso de uma carga escolhida do grupo consistindo de um derivado de celulose, e um derivado de amido - Google Patents
Formulação oral de liberação imediata na forma sólida de um inibidor de trombina, uso de um inibidor de trombina baseado em peptìdeo de baixo peso molecular, processos para a profilaxia e/ou o tratamento de trombo-embolismo, e para a preparação de uma formulação oral de liberação imediata, e, uso de uma carga escolhida do grupo consistindo de um derivado de celulose, e um derivado de amidoInfo
- Publication number
- BR9913400A BR9913400A BR9913400-4A BR9913400A BR9913400A BR 9913400 A BR9913400 A BR 9913400A BR 9913400 A BR9913400 A BR 9913400A BR 9913400 A BR9913400 A BR 9913400A
- Authority
- BR
- Brazil
- Prior art keywords
- immediate release
- thrombin inhibitor
- oral formulation
- molecular weight
- solid form
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
''FORMULAçãO ORAL DE LIBERAçãO IMEDIATA NA FORMA SóLIDA DE UM INIBIDOR DE TROMBINA, USO DE UM INIBIDOR DE TROMBINA BASEADO EM PEPTìDEO DE BAIXO PESO MOLECULAR, PROCESSOS PARA A PROFILAXIA E/OU O TRATAMENTO DE TROMBO-EMBOLISMO, E PARA A PREPARAçãO DE UMA FORMULAçãO ORAL DE LIBERAçãO IMEDIATA, E, USO DE UMA CARGA ESCOLHIDA DO GRUPO CONSISTINDO DE UM DERIVADO DE CELULOSE, E UM DERIVADO DE AMIDO". Uma nova formulação oral IR na forma sólida para um inibidor de trombina de baixo peso molecular tendo a dissolução dependente do pH, que se caracteriza pelo fato da formulação compreender uma carga ou uma combinação de cargas tendo propriedades desintegradoras em uma quantidade maior do que 35%, peso / peso, da formulação.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9802973A SE9802973D0 (sv) | 1998-09-03 | 1998-09-03 | Immediate release tablet |
PCT/SE1999/001471 WO2000013671A1 (en) | 1998-09-03 | 1999-08-27 | Immediate release tablet |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9913400A true BR9913400A (pt) | 2001-05-22 |
Family
ID=20412467
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9913400-4A BR9913400A (pt) | 1998-09-03 | 1999-08-27 | Formulação oral de liberação imediata na forma sólida de um inibidor de trombina, uso de um inibidor de trombina baseado em peptìdeo de baixo peso molecular, processos para a profilaxia e/ou o tratamento de trombo-embolismo, e para a preparação de uma formulação oral de liberação imediata, e, uso de uma carga escolhida do grupo consistindo de um derivado de celulose, e um derivado de amido |
Country Status (32)
Country | Link |
---|---|
US (3) | US6521253B1 (pt) |
EP (2) | EP1109537B1 (pt) |
JP (2) | JP4026678B2 (pt) |
KR (2) | KR100696350B1 (pt) |
CN (3) | CN1158070C (pt) |
AR (1) | AR029313A1 (pt) |
AT (1) | ATE286385T1 (pt) |
AU (1) | AU746129B2 (pt) |
BR (1) | BR9913400A (pt) |
CA (1) | CA2341397C (pt) |
CZ (1) | CZ300830B6 (pt) |
DE (1) | DE69923074T2 (pt) |
EE (1) | EE200100134A (pt) |
ES (1) | ES2234296T3 (pt) |
HU (1) | HU227278B1 (pt) |
ID (1) | ID29629A (pt) |
IL (2) | IL141439A0 (pt) |
IS (1) | IS5869A (pt) |
MY (1) | MY124359A (pt) |
NO (1) | NO20011085L (pt) |
NZ (2) | NZ539749A (pt) |
PL (1) | PL195603B1 (pt) |
PT (1) | PT1109537E (pt) |
RU (2) | RU2252751C2 (pt) |
SA (1) | SA99200683B1 (pt) |
SE (1) | SE9802973D0 (pt) |
SK (1) | SK285507B6 (pt) |
TR (2) | TR200100666T2 (pt) |
TW (1) | TW561056B (pt) |
UA (1) | UA75567C2 (pt) |
WO (1) | WO2000013671A1 (pt) |
ZA (1) | ZA200101762B (pt) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9802973D0 (sv) * | 1998-09-03 | 1998-09-03 | Astra Ab | Immediate release tablet |
SE9904377D0 (sv) * | 1999-12-01 | 1999-12-01 | Astra Pharma Prod | Pharmaceutical combinations |
CZ20024180A3 (cs) * | 2000-06-22 | 2003-04-16 | Novartis Ag | Pevné orální farmaceutické kompozice obsahující valsartan |
US6462021B1 (en) | 2000-11-06 | 2002-10-08 | Astrazeneca Ab | Use of low molecular weight thrombin inhibitor |
US7129233B2 (en) | 2000-12-01 | 2006-10-31 | Astrazeneca Ab | Mandelic acid derivatives and their use as thrombin inhibitors |
AR035216A1 (es) * | 2000-12-01 | 2004-05-05 | Astrazeneca Ab | Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios |
AR034517A1 (es) * | 2001-06-21 | 2004-02-25 | Astrazeneca Ab | Formulacion farmaceutica |
SE0103369D0 (sv) * | 2001-10-09 | 2001-10-09 | Astrazeneca Ab | Pharmaceutical formulation |
FR2833493B1 (fr) * | 2001-12-18 | 2005-09-23 | Ioltechnologie Production | Forme galenique solide et soluble pour l'administration occulaire de principes actifs et procede de fabrication d'un insert ophtalmique solide et soluble |
US20030181488A1 (en) | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof |
DK1488790T3 (da) * | 2002-03-28 | 2014-10-13 | Teijin Pharma Ltd | Fast præparat indeholdende en enkeltkrystalform A af etthiazolcarboxylsyrederivat |
SE0201658D0 (sv) * | 2002-05-31 | 2002-05-31 | Astrazeneca Ab | Immediate release pharmaceutical formulation |
SE0201659D0 (sv) * | 2002-05-31 | 2002-05-31 | Astrazeneca Ab | Modified release pharmaceutical formulation |
SE0201661D0 (sv) | 2002-05-31 | 2002-05-31 | Astrazeneca Ab | New salts |
US7479502B2 (en) | 2002-12-03 | 2009-01-20 | Pharmacyclics, Inc. | 2-(2-hydroxybiphenyl-3-yl)-1H-benzoimidazole-5-carboxamidine derivatives as factor VIIA inhibitors |
US7781424B2 (en) * | 2003-05-27 | 2010-08-24 | Astrazeneca Ab | Modified release pharmaceutical formulation |
WO2005065662A1 (en) * | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Solid dosage formulations of galantamine |
KR100574554B1 (ko) * | 2004-05-28 | 2006-04-27 | 한미약품 주식회사 | 니아신의 경구투여용 서방성 조성물 |
US8022053B2 (en) * | 2004-11-02 | 2011-09-20 | Bayer Schering Pharma Aktiengesellschaft | Oral solid dosage forms containing a low dose of estradiol |
US7524354B2 (en) * | 2005-07-07 | 2009-04-28 | Research Foundation Of State University Of New York | Controlled synthesis of highly monodispersed gold nanoparticles |
WO2008001672A1 (fr) * | 2006-06-29 | 2008-01-03 | Tsumura & Co. | Composition de comprimé contenant un extrait d'herbe chinoise |
TW200827336A (en) * | 2006-12-06 | 2008-07-01 | Astrazeneca Ab | New crystalline forms |
US8053440B2 (en) | 2007-02-01 | 2011-11-08 | Resverlogix Corporation | Compounds for the prevention and treatment of cardiovascular diseases |
US20090061000A1 (en) * | 2007-08-31 | 2009-03-05 | Astrazeneca Ab | Pharmaceutical formulation use 030 |
DE102008014237A1 (de) * | 2008-03-14 | 2009-09-17 | J. Rettenmaier & Söhne Gmbh + Co. Kg | Direktverpressbares Tablettierhilfsmittel |
EP2407166B1 (en) * | 2009-03-13 | 2013-08-21 | Toyama Chemical Co., Ltd. | Tablet and granulated powder containing 6-fluoro-3-hydroxy-2-pyrazinecarboxamide |
BRPI1009315B8 (pt) | 2009-03-18 | 2021-05-25 | Resverlogix Corp | composto anti-flamatórios e suas composições farmacêuticas |
TR201818390T4 (tr) | 2009-04-22 | 2019-01-21 | Resverlogix Corp | Yeni̇ anti̇-i̇nflamatuvar ajanlar |
PL2773354T3 (pl) * | 2011-11-01 | 2019-12-31 | Resverlogix Corp. | Doustna formulacja o natychmiastowym uwalnianiu dla podstawowych chinazolinów |
US10213421B2 (en) | 2012-04-04 | 2019-02-26 | Alkahest, Inc. | Pharmaceutical formulations comprising CCR3 antagonists |
US9073878B2 (en) | 2012-11-21 | 2015-07-07 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
WO2014080291A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Biaryl derivatives as bromodomain inhibitors |
CA2895905A1 (en) | 2012-12-21 | 2014-06-26 | Zenith Epigenetics Corp. | Novel heterocyclic compounds as bromodomain inhibitors |
GB201400034D0 (en) * | 2014-01-02 | 2014-02-19 | Astrazeneca Ab | Pharmaceutical Compositions comprising AZD9291 |
US10111885B2 (en) | 2015-03-13 | 2018-10-30 | Resverlogix Corp. | Compositions and therapeutic methods for the treatment of complement-associated diseases |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1601833A (en) | 1978-02-06 | 1981-11-04 | Wellcome Found | Antacid formulation |
US4517179A (en) * | 1983-04-29 | 1985-05-14 | Pennwalt Corporation | Rapid dissolving, uniform drug compositions and their preparation |
IT1200178B (it) | 1986-07-23 | 1989-01-05 | Alfa Farmaceutici Spa | Formulazioni galeniche a cessione programmata contenenti farmaci ad attivita' antiflogistica |
AR240018A1 (es) * | 1987-10-07 | 1990-01-31 | Merrell Pharma Inc | Procedimiento para preparar una composicion que comprende derivados de piperidinoalcanol. |
US5430023A (en) | 1990-09-28 | 1995-07-04 | Eli Lilly And Company | Tripeptide antithrombotic agents |
SE9102462D0 (sv) | 1991-08-28 | 1991-08-28 | Astra Ab | New isosteric peptides |
SE9103612D0 (sv) * | 1991-12-04 | 1991-12-04 | Astra Ab | New peptide derivatives |
US5532267A (en) | 1992-02-10 | 1996-07-02 | Torii & Co., Ltd. | Amidinonaphthyl furancarboxylate derivatives and acid addition salts therof |
US5470955A (en) | 1993-02-02 | 1995-11-28 | Dartmouth College | Antibodies which specifically bind mcl-1 polypeptide |
SE9301916D0 (sv) | 1993-06-03 | 1993-06-03 | Ab Astra | New peptides derivatives |
US5436229A (en) * | 1994-03-04 | 1995-07-25 | Eli Lilly And Company | Bisulfite adducts of arginine aldehydes |
HUT78132A (hu) | 1994-07-08 | 2000-06-28 | Astra Aktiebolag | Omeprazol magnéziumsóját tartalmazó új orális gyógyszerforma |
US5510369A (en) * | 1994-07-22 | 1996-04-23 | Merck & Co., Inc. | Pyrrolidine thrombin inhibitors |
DE19530575A1 (de) * | 1995-08-19 | 1997-02-20 | Gruenenthal Gmbh | Schnell zerfallende Arzneiform von Tramadol oder einem Tramadolsalz |
US5733578A (en) | 1995-11-15 | 1998-03-31 | Edward Mendell Co., Inc. | Directly compressible high load acetaminophen formulations |
TW430561B (en) | 1995-12-20 | 2001-04-21 | Gea Farmaceutisk Fabrik As | Rapid release tablet composition comprising tolfenamic acid or a pharmaceutically acceptable salt thereof as active ingredient and a method of preparing such tablet |
AR005245A1 (es) * | 1995-12-21 | 1999-04-28 | Astrazeneca Ab | Prodrogas de inhibidores de trombina, una formulación farmaceutica que las comprende, el uso de dichas prodrogas para la manufactura de un medicamento y un procedimiento para su preparacion |
EP0803251B1 (en) * | 1996-04-23 | 2002-07-17 | Janssen Pharmaceutica N.V. | Immediate release pH-independent solid dosage form of cisapride |
SE9601556D0 (sv) * | 1996-04-24 | 1996-04-24 | Astra Ab | New pharmaceutical formulation of a thrombin inhibitor for parenteral use |
DE19628617A1 (de) * | 1996-07-16 | 1998-01-22 | Basf Ag | Direkttablettierhilfsmittel |
JP2001500875A (ja) * | 1996-09-18 | 2001-01-23 | メルク エンド カンパニー インコーポレーテッド | 心臓血管系疾患関連の危険性を減らす併用治療法 |
HRP970493A2 (en) * | 1996-09-23 | 1998-08-31 | Wienman E. Phlips | Oral delayed immediate release medical formulation and method for preparing the same |
SE9603724D0 (sv) * | 1996-10-11 | 1996-10-11 | Astra Ab | New pharmaceutical parenteral formulation of a thrombin inhibitor |
US5798377A (en) * | 1996-10-21 | 1998-08-25 | Merck & Co., Inc. | Thrombin inhibitors |
UA69413C2 (uk) | 1998-05-22 | 2004-09-15 | Брістол-Майерс Сквібб Компані | Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції |
GB9814215D0 (en) | 1998-07-01 | 1998-09-02 | Norton Healthcare Ltd | Anti-inflammatory pharmaceutical formulations |
CA2239931A1 (en) | 1998-07-15 | 2000-01-15 | Bernard Charles Sherman | Pharmaceutical tablet comprising norfloxacin |
US6368625B1 (en) | 1998-08-12 | 2002-04-09 | Cima Labs Inc. | Orally disintegrable tablet forming a viscous slurry |
SE9802973D0 (sv) * | 1998-09-03 | 1998-09-03 | Astra Ab | Immediate release tablet |
US6602521B1 (en) | 1998-09-29 | 2003-08-05 | Impax Pharmaceuticals, Inc. | Multiplex drug delivery system suitable for oral administration |
CA2366791A1 (en) | 1999-04-06 | 2000-10-12 | Kamal K. Midha | Pharmaceutical dosage form for pulsatile delivery of d-threo-methylphenidate and a second cns stimulant |
NL1014915C2 (nl) | 1999-04-13 | 2001-02-12 | Beecham Pharm Pte Ltd | Nieuwe behandelingsmethode. |
-
1998
- 1998-09-03 SE SE9802973A patent/SE9802973D0/xx unknown
-
1999
- 1999-08-24 TW TW088114460A patent/TW561056B/zh not_active IP Right Cessation
- 1999-08-27 CZ CZ20010774A patent/CZ300830B6/cs not_active IP Right Cessation
- 1999-08-27 DE DE69923074T patent/DE69923074T2/de not_active Expired - Lifetime
- 1999-08-27 CN CNB998103365A patent/CN1158070C/zh not_active Expired - Fee Related
- 1999-08-27 EP EP99946527A patent/EP1109537B1/en not_active Expired - Lifetime
- 1999-08-27 UA UA2001021082A patent/UA75567C2/uk unknown
- 1999-08-27 PT PT99946527T patent/PT1109537E/pt unknown
- 1999-08-27 AU AU58924/99A patent/AU746129B2/en not_active Ceased
- 1999-08-27 SK SK281-2001A patent/SK285507B6/sk not_active IP Right Cessation
- 1999-08-27 IL IL14143999A patent/IL141439A0/xx active IP Right Grant
- 1999-08-27 ES ES99946527T patent/ES2234296T3/es not_active Expired - Lifetime
- 1999-08-27 NZ NZ539749A patent/NZ539749A/en not_active IP Right Cessation
- 1999-08-27 HU HU0103886A patent/HU227278B1/hu not_active IP Right Cessation
- 1999-08-27 AT AT99946527T patent/ATE286385T1/de not_active IP Right Cessation
- 1999-08-27 EE EEP200100134A patent/EE200100134A/xx unknown
- 1999-08-27 CA CA002341397A patent/CA2341397C/en not_active Expired - Fee Related
- 1999-08-27 BR BR9913400-4A patent/BR9913400A/pt not_active Application Discontinuation
- 1999-08-27 JP JP2000568480A patent/JP4026678B2/ja not_active Expired - Fee Related
- 1999-08-27 TR TR2001/00666T patent/TR200100666T2/xx unknown
- 1999-08-27 RU RU2001104423/15A patent/RU2252751C2/ru not_active IP Right Cessation
- 1999-08-27 EP EP04030515A patent/EP1527787A1/en active Pending
- 1999-08-27 CN CNA200410038573XA patent/CN1544088A/zh active Pending
- 1999-08-27 PL PL99346545A patent/PL195603B1/pl not_active IP Right Cessation
- 1999-08-27 KR KR1020017002726A patent/KR100696350B1/ko not_active IP Right Cessation
- 1999-08-27 ID IDW20010429A patent/ID29629A/id unknown
- 1999-08-27 NZ NZ509943A patent/NZ509943A/en not_active IP Right Cessation
- 1999-08-27 TR TR2005/02188T patent/TR200502188T2/xx unknown
- 1999-08-27 WO PCT/SE1999/001471 patent/WO2000013671A1/en active IP Right Grant
- 1999-08-27 CN CNA2006100996728A patent/CN1951371A/zh active Pending
- 1999-08-27 KR KR1020067017052A patent/KR20060097071A/ko not_active Application Discontinuation
- 1999-08-27 US US09/424,740 patent/US6521253B1/en not_active Expired - Fee Related
- 1999-09-01 MY MYPI99003778A patent/MY124359A/en unknown
- 1999-09-02 AR ARP990104423A patent/AR029313A1/es not_active Application Discontinuation
- 1999-10-18 SA SA99200683A patent/SA99200683B1/ar unknown
-
2001
- 2001-02-15 IL IL141439A patent/IL141439A/en not_active IP Right Cessation
- 2001-02-28 IS IS5869A patent/IS5869A/is unknown
- 2001-03-01 ZA ZA200101762A patent/ZA200101762B/xx unknown
- 2001-03-02 NO NO20011085A patent/NO20011085L/no not_active Application Discontinuation
-
2003
- 2003-01-21 US US10/347,968 patent/US6875446B2/en not_active Expired - Fee Related
-
2005
- 2005-01-19 RU RU2005100986/15A patent/RU2005100986A/ru not_active Application Discontinuation
- 2005-03-31 US US11/095,933 patent/US20050208128A1/en not_active Abandoned
-
2006
- 2006-11-16 JP JP2006309957A patent/JP2007039472A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9913400A (pt) | Formulação oral de liberação imediata na forma sólida de um inibidor de trombina, uso de um inibidor de trombina baseado em peptìdeo de baixo peso molecular, processos para a profilaxia e/ou o tratamento de trombo-embolismo, e para a preparação de uma formulação oral de liberação imediata, e, uso de uma carga escolhida do grupo consistindo de um derivado de celulose, e um derivado de amido | |
EE9600072A (et) | Uudne ravimsegu, mis sisaldab ACE inhibiitorit ramipriili ja dihüdropüridiinühendit | |
BRPI0316532B8 (pt) | composições farmacêuticas compreendendo uma droga básica ou ácida, um tensoativo, e um ácido ou base solúvel em água fisiologicamente tolerável | |
PT100850A (pt) | Composicoes farmaceuticas contendo uma mistura sinergica de um agente uricosurico, em especial,de probenecid, com um agente antagonista de aminoacidos excitantes, em especial,um derivado de quinoxalina substituido e sua utilizacao no tratamento de doencas neurodegenerativas | |
YU92501A (sh) | Levodop/karbidop/entakapon farmaceutski preparat | |
BR9811099A (pt) | Inibidores de urocinase | |
ES2174920T3 (es) | Producto de combinacion para la contracepcion que contiene agentes antagonistas de progesterona y un agente gestageno. | |
BR0008059A (pt) | Composições de valdecoxib | |
BR9913239A (pt) | Comprimido bioadesivo bucal de liberação prolongada | |
BR9910180A (pt) | Composição farmacêutica, processos para o tratamento de uma condição associada com a transmissão reduzida de nicotina, para identificação de um modulador positivo de um agonista receptor nicotìnico e para identificação de um composto, composto, e, uso de um modulador positivo de um agonista receptor nicotìnico | |
FR2733427B1 (fr) | Compositions biphasiques injectables renfermant de l'acide hyaluronique, notamment utiles en chirurgies reparatrice et esthetique | |
BR9711194A (pt) | Uso de agente quelante clioquinol para a fabricação de uma composição farmacêutica para o tratamento de doença de alzheimer. | |
PT979244E (pt) | Derivados de ciclosporina, sua preparacao e composicoes farmaceuticas que os contem | |
BR0013219A (pt) | Métodos de tratamento ou inibição de pólipos de cólon, de tratamento ou inibição de câncer colorretal, uso de uma combinação de nsaid e de um inibidor de egfr quinase, composição farmacêutica, e, produto | |
ATE272628T1 (de) | Substituierte gamma-phenyl-delta-lactone und deren analoge, und ihre verwendungen | |
BR9811478A (pt) | Composições de polìmero-ácido tânico para a liberação controlada de agentes farmacêuticos particularmente na cavidade oral | |
BR9913681A (pt) | Composição farmacêutica compreendendo entacapona ou nitecapona, assim como um derivado de celulose reticulada | |
AR015966A1 (es) | Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito | |
BR0212907A (pt) | Métodos para tratamento ou prevenção de inflamação vascular usando inibidor(es) da absorção de esteróis | |
DK0521388T3 (da) | Fremgangsmåde til fremstilling af et farmaceutisk præparat med mindst to forskellige aktivstoffer samt anvendelsen af et sådant præparat | |
BR9811914A (pt) | Composição sólida para reduzir a erosão dos dentes | |
BR0214810A (pt) | Combinação de um inibidor de il-1/18 com um inibidor de tnf para o tratamento de inflamação | |
DK1269860T3 (da) | Farmaceutisk præparat | |
BR9816029A (pt) | Composições detergente | |
BR0213357A (pt) | Compostos orgânicos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 11, 10(VIII), 13 E 25 DA LPI |
|
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |